PE20121540A1 - Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada - Google Patents

Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada

Info

Publication number
PE20121540A1
PE20121540A1 PE2011001896A PE2011001896A PE20121540A1 PE 20121540 A1 PE20121540 A1 PE 20121540A1 PE 2011001896 A PE2011001896 A PE 2011001896A PE 2011001896 A PE2011001896 A PE 2011001896A PE 20121540 A1 PE20121540 A1 PE 20121540A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
ngf
growth factor
improved
Prior art date
Application number
PE2011001896A
Other languages
English (en)
Inventor
John Powell
Mark Maginn
Duncan Casson
Andrea Best
Sandeep Dutta
Jerry A Hall
Wei Liu
Original Assignee
Abbott Res Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Res Bv filed Critical Abbott Res Bv
Publication of PE20121540A1 publication Critical patent/PE20121540A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN ANTICUERPO ANTI-FACTOR DE CRECIMIENTO NERVIOSO (NGF) QUE COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE LA SECUENCIA DE AMINOACIDO DE LA SEC ID Nº 1 Y LAS CDRs 1, 2 Y 3 QUE TIENEN LAS SECUENCIAS DE AMINOACIDO DE LAS SEC ID Nº 3, 4 Y 5 RESPECTIVAMENTE; B) UNA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE LA SECUENCIA DE AMINOACIDO DE LA SEC ID Nº 2 Y LAS CDRs 1, 2 Y 3 QUE TIENEN LAS SECUENCIAS DE AMINOACIDO DE LAS SEC ID Nº 6, 7 Y 8 RESPECTIVAMENTE; Y C) UNA REGION CONSTANTE DE IgG4 HUMANA QUE COMPRENDE LA SECUENCIA DE AMINOACIDO DE LA SEC ID Nº 10. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA SIENDO UTIL EN EL TRATAMIENTO DEL DOLOR
PE2011001896A 2009-05-04 2010-05-04 Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada PE20121540A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17522809P 2009-05-04 2009-05-04
US22725109P 2009-07-21 2009-07-21
US23881309P 2009-09-01 2009-09-01
US25231409P 2009-10-16 2009-10-16

Publications (1)

Publication Number Publication Date
PE20121540A1 true PE20121540A1 (es) 2012-12-22

Family

ID=43030513

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001896A PE20121540A1 (es) 2009-05-04 2010-05-04 Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada

Country Status (31)

Country Link
US (2) US8435523B2 (es)
EP (1) EP2448970B1 (es)
JP (2) JP5898064B2 (es)
KR (1) KR20120088550A (es)
CN (1) CN102459337B (es)
AR (1) AR076650A1 (es)
AU (1) AU2010244133B2 (es)
BR (1) BRPI1014445A8 (es)
CA (1) CA2761203A1 (es)
CL (1) CL2011002765A1 (es)
CO (1) CO6470819A2 (es)
CR (1) CR20110629A (es)
DK (1) DK2448970T3 (es)
DO (1) DOP2011000337A (es)
EC (1) ECSP11011502A (es)
ES (1) ES2514319T3 (es)
HK (1) HK1170508A1 (es)
HR (1) HRP20140915T1 (es)
IL (1) IL216128A (es)
MX (1) MX2011011728A (es)
NZ (1) NZ596839A (es)
PE (1) PE20121540A1 (es)
PL (1) PL2448970T3 (es)
PT (1) PT2448970E (es)
RU (1) RU2549679C2 (es)
SG (1) SG175436A1 (es)
SI (1) SI2448970T1 (es)
TW (1) TWI486171B (es)
UA (1) UA104890C2 (es)
UY (1) UY32608A (es)
WO (1) WO2010128398A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587852A (en) 2002-12-24 2012-02-24 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME02239B (me) 2007-08-10 2015-04-30 Regeneron Pharma Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
DK2448970T3 (da) 2009-05-04 2014-10-06 Abbvie Res B V Antistoffer mod nervevækstfaktor (ngf) med forbedret in vivo-stabilitet
JP2013522313A (ja) 2010-03-17 2013-06-13 アボツト・リサーチ・ベー・フエー 抗神経成長因子（ｎｇｆ）抗体組成物
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
WO2012083370A1 (en) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
CA2834983C (en) 2011-05-06 2020-11-17 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
LT2743348T (lt) 2011-08-11 2018-05-10 Astellas Pharma Inc. Naujas žmogaus anti-naf antikūnas
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
KR200480634Y1 (ko) 2015-04-14 2016-06-16 한전케이피에스 주식회사 긴급복구용 윈치의 고정장치
JP6700620B2 (ja) 2015-05-22 2020-05-27 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
IT201700066486A1 (it) * 2017-06-15 2018-12-15 Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
JPWO2019221097A1 (ja) 2018-05-15 2021-05-27 アステラス製薬株式会社 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物
GB2579707A (en) 2018-10-15 2020-07-01 Avent Inc Compositions, systems, kits, and methods for neural ablation
WO2020248942A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗β-NGF纳米抗体及其应用
CN110583625A (zh) * 2019-09-17 2019-12-20 深圳大学 一种脐带储存液
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Ampsource Biopharma Shanghai Inc. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
CN116178541A (zh) * 2020-08-06 2023-05-30 熙源安健医药（上海）有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
WO2023004784A1 (zh) 2021-07-30 2023-02-02 成都优洛生物科技有限公司 一种重组cho细胞、其构建方法、利用其的检测***和方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU9164991A (en) 1990-11-30 1992-06-25 Abbott Laboratories Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
EP0578515A3 (en) 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DE60044149D1 (de) 1999-08-06 2010-05-20 S I S S A Scuola Internaz Supe Transgene mäuse zur studierung von neurodegenerativen syndromen
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
EP2340849A1 (en) 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
CA2500901A1 (en) 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003285864C1 (en) 2002-10-08 2010-07-01 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
ATE480562T1 (de) * 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
NZ587852A (en) 2002-12-24 2012-02-24 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20060147932A1 (en) 2003-01-18 2006-07-06 Alun Davies Methods of screening for modulators of nerve growth factor
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
ES2355558T3 (es) * 2003-02-19 2011-03-28 Rinat Neuroscience Corp. Procedimiento para tratar el dolor administrando un antagonista del factor de crecimiento neuronal y un aine y la composición que contiene los mismos.
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
TWI635096B (zh) 2003-07-15 2018-09-11 安美基公司 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
WO2005044293A2 (en) 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
PL1732949T3 (pl) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ES2387312T3 (es) 2004-09-22 2012-09-20 Kyowa Hakko Kirin Co., Ltd. Anticuerpos IgG4 humanos estabilizados
EP1819728B1 (en) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7 variants with reduced immunogenicity
EP2298345A3 (en) 2005-01-24 2012-03-21 MedImmune Limited Specific binding members for NGF
ES2864039T3 (es) 2005-05-20 2021-10-13 Lonza Biologics Plc Expresión de alto nivel de un anticuerpo recombinante en una célula huésped de mamífero
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
CA2672902C (en) 2006-12-21 2012-11-27 Amgen Inc. Formulations
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
ME02239B (me) 2007-08-10 2015-04-30 Regeneron Pharma Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
KR101499278B1 (ko) 2007-12-17 2015-03-06 화이자 리미티드 간질성 방광염의 치료
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
DK2448970T3 (da) * 2009-05-04 2014-10-06 Abbvie Res B V Antistoffer mod nervevækstfaktor (ngf) med forbedret in vivo-stabilitet
WO2011000020A1 (en) 2009-06-12 2011-01-06 Sbc Research Pty Ltd Enhanced method of detection
JP2013522313A (ja) 2010-03-17 2013-06-13 アボツト・リサーチ・ベー・フエー 抗神経成長因子（ｎｇｆ）抗体組成物

Also Published As

Publication number Publication date
UY32608A (es) 2010-12-31
US8435523B2 (en) 2013-05-07
AU2010244133A1 (en) 2011-12-15
HRP20140915T1 (hr) 2014-12-05
TW201043246A (en) 2010-12-16
KR20120088550A (ko) 2012-08-08
CL2011002765A1 (es) 2012-07-20
ES2514319T3 (es) 2014-10-28
CA2761203A1 (en) 2010-11-11
NZ596839A (en) 2014-01-31
SG175436A1 (en) 2011-12-29
US9447181B2 (en) 2016-09-20
CN102459337A (zh) 2012-05-16
TWI486171B (zh) 2015-06-01
AR076650A1 (es) 2011-06-29
ECSP11011502A (es) 2012-04-30
CN102459337B (zh) 2015-05-20
DOP2011000337A (es) 2012-02-15
SI2448970T1 (sl) 2014-11-28
US20100278839A1 (en) 2010-11-04
EP2448970B1 (en) 2014-07-09
HK1170508A1 (en) 2013-03-01
DK2448970T3 (da) 2014-10-06
RU2549679C2 (ru) 2015-04-27
EP2448970A1 (en) 2012-05-09
MX2011011728A (es) 2012-04-19
CO6470819A2 (es) 2012-06-29
IL216128A (en) 2015-10-29
PL2448970T3 (pl) 2014-12-31
JP5898064B2 (ja) 2016-04-06
IL216128A0 (en) 2012-01-31
WO2010128398A1 (en) 2010-11-11
JP2016026221A (ja) 2016-02-12
BRPI1014445A8 (pt) 2018-01-09
PT2448970E (pt) 2014-10-20
BRPI1014445A2 (pt) 2016-11-29
CR20110629A (es) 2012-05-28
US20130295112A1 (en) 2013-11-07
RU2011149263A (ru) 2013-06-10
JP2012525838A (ja) 2012-10-25
UA104890C2 (uk) 2014-03-25
AU2010244133B2 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
PE20121540A1 (es) Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
PE20121649A1 (es) Anticuerpos monoclonales frente a progastrina y sus usos
EA201370126A1 (ru) Человеческие антитела к рецептору глюкагона
PE20110561A1 (es) Anticuerpos contra il-6
AR079903A1 (es) Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit.
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
AR089507A1 (es) VARIANTES DE Fc DE INMUNOGLOBULINAS
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201300016A1 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами
PE20130528A1 (es) PROTEINAS QUE SE UNEN AL TNF-alfa
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
PE20120562A1 (es) Anticuerpo anti-axl
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
EA200600254A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
AR074756A1 (es) Anticuerpos contra la angiopoyetina-2 humana
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed